靶向治疗——持续残留病灶。
Targeting therapy-persistent residual disease.
发表日期：2024 Sep
作者：
Xiaoxiao Sun, Lani F Wu, Steven J Altschuler, Aaron N Hata
来源：
Nature Cancer
摘要：
由获得性耐药性导致的疾病复发限制了大多数全身抗癌药物的有效性。在复发前针对残留疾病中的持续性癌细胞已成为增强当前疗法的疗效和持久性的潜在策略。然而，在临床上实施坚持者导向的方法仍然存在障碍。本观点讨论了当前临床前和临床的复杂性，并概述了制定针对治疗持续性残留疾病的临床策略的关键步骤。© 2024。Springer Nature America, Inc.
Disease relapse driven by acquired drug resistance limits the effectiveness of most systemic anti-cancer agents. Targeting persistent cancer cells in residual disease before relapse has emerged as a potential strategy for enhancing the efficacy and the durability of current therapies. However, barriers remain to implementing persister-directed approaches in the clinic. This Perspective discusses current preclinical and clinical complexities and outlines key steps toward the development of clinical strategies that target therapy-persistent residual disease.© 2024. Springer Nature America, Inc.